| Literature DB >> 34884409 |
Alexandra Caziuc1, Diana Schlanger2, Giorgiana Amarinei1, Vlad Fagarasan1, David Andras1, George Calin Dindelegan1.
Abstract
INTRODUCTION: Our study aimed to determine the feasibility of axillary reverse mapping (ARM) technique, the identification rate of ARM nodes and their metastatic involvement, as well as to identify the factors that influence the identification and metastatic involvement.Entities:
Keywords: axillary reverse mapping; breast cancer; lymph node; lymphedema; metastases
Year: 2021 PMID: 34884409 PMCID: PMC8658501 DOI: 10.3390/jcm10235707
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Population study and factors that might influence ARM node identification.
| Parameter | Population Study | Identified ARM Nodes ( | Unidentified ARM Nodes ( | |
|---|---|---|---|---|
| Age * | 56.73 ± 12.56 | 56.67 ± 12.61 | 56.83 ± 13.05 | 0.068 |
| BMI * | 27.08 ± 5.63 | 25.06 ± 4.78 | 30.12 ± 5.61 | 0.013 |
| Tumor size ** | 0.35 | |||
| T1 | 12 | 8 | 4 | |
| T2 | 13 | 7 | 6 | |
| T3 | 2 | 1 | 1 | |
| T4 | 3 | 2 | 1 | |
| Pathological lymph node status (pN) ** | 0.0001 | |||
| pN0 | 14 | 10 | 4 | |
| pN1 | 9 | 4 | 5 | |
| pN2 | 5 | 2 | 3 | |
| pN3 | 2 | 2 | 0 | |
| Hystological type ** | 0.54 | |||
| NST | 25 | 15 | 10 | |
| Lobular | 4 | 3 | 1 | |
| Other | 1 | 0 | 1 | |
| Intrinsic subtype ** | 0.39 | |||
| Luminal A | 16 | 5 | 11 | |
| Luminl B Her 2− | 13 | 7 | 6 | |
| Luminal B Her 2+ | 6 | 4 | 2 | |
| HER 2 overexpressed | 1 | 1 | 0 | |
| Triple negative | 3 | 1 | 2 | |
| Grade ** | 0.338 | |||
| G1 | 4 | 2 | 2 | |
| G2 | 18 | 12 | 6 | |
| G3 | 8 | 4 | 4 | |
| Neoadjuvant treatment ** | 0.51 | |||
| ChT | 15 | 7 | 8 | |
| HT | 4 | 2 | 2 | |
| Localization ** | 0.52 | |||
| UOQ | 15 | 9 | 6 | |
| UIQ | 2 | 1 | 1 | |
| LOQ | 3 | 2 | 1 | |
| LIQ | 2 | 1 | 1 | |
| Central | 2 | 1 | 1 | |
| Multicentric/multifocal | 6 | 4 | 2 |
* Variables described as average ± SD. ** Variables described as number of patients. BMI—body mass index. ChT—neoadjuvant chemotherapy. HT—neoadjuvant hormonal therapy. UOQ—upper outer quadrant. UIQ—upper inner quadrant. LOQ—lower outer quadrant. LIQ—lower inner quadrant.
Figure 1Axillary dissection—ARM node colored in blue.
Factors that might influence metastatic involvement of ARM node.
| Factor | Positive ARM Nodes | Negative ARM Nodes |
|
|---|---|---|---|
| Average age * | 53.79 ± 10.05 | 66.75 ± 16.99 | 0.068 |
| Average BMI * | 24.67 ± 4.13 | 26.42 ± 7.23 | 0.53 |
| Axillary lymph node status ** | 0.0001 | ||
| pN0 | 10 | 0 | |
| pN1 | 4 | 0 | |
| pN2 | 0 | 2 | |
| pN3 | 0 | 2 | |
| Tumor size ** | 0.35 | ||
| T1 | 7 | 1 | |
| T2 | 5 | 2 | |
| T3 | 1 | 0 | |
| T4 | 1 | 1 | |
| Histological grade ** | 0.338 | ||
| G1 | 2 | 0 | |
| G2 | 9 | 3 | |
| G3 | 3 | 1 | |
| Neoadjuvant chemotherapy ** | 6 | 1 | 0.51 |
| Histological type ** | 0.54 | ||
| NST | 12 | 3 | |
| Lobular | 2 | 1 | |
| Molecular subtype ** | 0.39 | ||
| Triple negative | 1 | 0 | |
| Luminal A | 4 | 1 | |
| Luminal B Her2 positive | 3 | 1 | |
| Luminal B Her2 negative | 6 | 1 | |
| Her2 overexpression | 0 | 1 |
* Variables described as average ± SD. ** Variables described as number of patients. BMI—body mass index.